Teva Announces Launch of Generic Glumetza in the United Stat

Teva Pharmaceutical Industries Ltd announced the launch of generic Glumetza®1 (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in the U.S.



Metformin hydrochloride extended-release tablets are used with diet and exercise to help control high blood sugar in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are not for people with type 1 diabetes or for
people with diabetic ketoacidosis.

More than 28 million people in the U.S. are living with type 2 diabetes2; a serious disease that can be managed through physical activity, diet and appropriate use of medications to lower blood sugar levels.

Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.

Glumetza® had annual sales of approximately $1.03 billion in the U.S. according to IMS data as of March 2017.


About Metformin Hydrochloride Extended-Release Tablets

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use: Metformin hydrochloride extended-release tablets should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.


About Teva
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com


Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin C. Mannix, 215-591-8912
or

Ran Meir, 215-591-3033

or

Israel

Tomer Amitai, 972 (3) 926-7656
or

PR Contacts:

Israel
Iris Beck Codner, 972 (3) 926-7687
or

United States

Denise Bradley, 215-591-8974
or
Nancy Leone, 215-284-0213

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: